Ensemble Discovery is developing novel classes of therapeutics and bioassays using its proprietary DNA-Programmed Chemistry™ (DPC™) platform. DPC provides unprecedented control of chemical reactivity, enabling the synthesis of diverse compounds for use in drug discovery and biodetection.

Our therapeutic business is developing Programmed Macrocycles™ as a new therapeutic class for use against types of targets that have been historically challenging to the pharmaceutical industry.

Our detection business is developing Programmed Bioassays™ to control the generation of signaling molecules in assays of protein functionality, enabling novel research tools and diagnostic products.